https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5071 Wed 11 Apr 2018 13:20:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5069 Wed 11 Apr 2018 10:11:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8459 Sat 24 Mar 2018 08:38:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8460 Sat 24 Mar 2018 08:38:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12306 2 = 79%). When the four trials by Boldt are excluded, the RR is 0.76 (95% CI 0.62 to 0.93). On average, PRP did not significantly reduce the total volume of RBC transfused (weighted mean difference [WMD] -0.69, 95%CI -1.93 to 0.56 units). Trials provided inadequate data regarding the impact of PRP on morbidity, mortality, and hospital length of stay. Trials were generally small and of poor methodological quality. Authors' conclusions: Although the results suggest that PRP is effective in reducing allogeneic RBC transfusion in adult patients undergoing elective surgery, there was considerable heterogeneity of treatment effects and the trials were of poor methodological quality. The available studies provided inadequate data for firm conclusions to be drawn regarding the impact of PRP on clinically important endpoints.]]> Sat 24 Mar 2018 08:11:35 AEDT ]]>